This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
by Zacks Equity Research
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
by Sundeep Ganoria
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
FDA Approves Updated COVID-19 Vaccines but With Restrictions
by Zacks Equity Research
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
by Zacks Equity Research
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of +985.71% and +102.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novavax (NVAX) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
by Zacks Equity Research
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
Novavax (NVAX) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $6.61 in the latest trading session, marking a -2.79% move from the prior day.
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ginkgo Bioworks (DNA) Soars 18.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ginkgo Bioworks (DNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.